drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy / cellular immunotherapy (CAR T)
drug_description
Autologous T cells genetically engineered to co-express a bispecific chimeric antigen receptor targeting CD19 and CD22, activating T-cell cytotoxicity against B-ALL blasts and reducing antigen-loss escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to co-express a bispecific chimeric antigen receptor that recognizes CD19 and CD22 on B-ALL cells. CAR engagement activates T-cell signaling, driving proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity, while dual targeting reduces antigen-loss escape compared with single-antigen CARs.
drug_name
CD19x22 CAR T cells
nct_id_drug_ref
NCT06559189